Current treatment options for primary CNS lymphoma (PCNSL) are limited, and there are no medications approved specifically for the treatment of PCNSL in the United States. New treatment options are needed to improve the prognosis for those with PCNSL.
The PROSPECT study is a clinical trial to evaluate an investigational oral medicine called tirabrutinib in patients with PCNSL. About 112 participants will be enrolled in the Phase II (PROSPECT) study in the United States.
End Brain Cancer Mobile App is Here
Stay informed and engaged with EBCI, download our new mobile app.